Insmed (INSM) is up ~13% in Thursday trading after reporting Q3 financial results that beat on revenue and raising full-year revenue guidance for its two marketed therapies.
The company sees Brinsupri (brensocatib) revenue of $1.35B-$1.4B, up from $1.25B-$1.40B prior
Arikayce ( To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser